Research Article Details
| Article ID: | A26114 |
| PMID: | 21073123 |
| Source: | J Pediatr Endocrinol Metab |
| Title: | Mean platelet volume in obese adolescents with nonalcoholic fatty liver disease. |
| Abstract: | BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the accumulation of excess fat in the liver in the absence of alcohol consumption, which commonly coexists with obesity. NAFLD is associated with increased risk of atherosclerosis and insulin resistance. Mean platelet volume (MPV) is a marker of platelet activation, which is a determinant of atherosclerosis. AIMS: The first aim of the present study was to investigate the MPV levels in obese adolescents and compare the MPV levels in patients with and without NAFLD and also with healthy controls. The second aim of this study was to evaluate the relationship between IR and MPV. PATIENTS AND METHODS: Case records of 128 exogenous obese adolescents were retrospectively evaluated. Laboratory parameters were collected by using a computerized patient database. Insulin resistance was calculated by a homeostasis model assessment (HOMA-IR) index. Patients were divided into two groups: patients with NAFLD (Group 1) and patients without NAFLD (Group 2). Forty-seven healthy children constituted the control group. RESULTS: MPV was significantly higher in obese adolescents than their healthy peers. Group 1 had significantly higher MPV than group 2. HOMA-IR was significantly higher in group 1 than group 2. MPV was significantly higher in patients with IR than patients without IR. There was a positive correlation between MPV and HOMA-IR. MPV was inversely correlated with HDL cholesterol and platelet count. CONCLUSION: MPV may be used as a follow-up marker in patients with NAFLD at the point of atherosclerosis. |
| DOI: | 10.1515/jpem.2010.130 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| I07 | 1936 | Arteriosclerosis | Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C35768 | disease of anatomical entity/cardiovascular system disease/ vascular disease/ artery disease | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |